Administrative Core

行政核心

• 批准号: 10026251
• 负责人: CRAIG J. MCCLAIN
• 金额: $ 60.75万
• 依托单位: UNIVERSITY OF LOUISVILLE
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-06-10 至 2026-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10026251
• 关键词: Acute Liver Failure; Adult; Affect; Alcoholic Liver Diseases; Alcohols; American; Area; Bioinformatics; Biometry; Budgets; Cancer Grant Supplements (P30); Centers of Research Excellence; Child; Clinical Trials; Communities; Community Outreach; Conflict (Psychology); Country; Development; Development Plans; Diabetes Mellitus; Drug Interactions; Drug abuse; Ensure; Environment; Environmental Health; Enzymes; Evaluation; FDA approved; Faculty; Funding; Goals; Grant; Health; Hepatitis A; Hepatitis C; Homelessness; Human Resources; Individual; Industrialization; Italy; Kentucky; Letters; Liver; Liver diseases; Malignant neoplasm of liver; Mentors; Morbidity - disease rate; National Institute of Environmental Health Sciences; National Institute on Alcohol Abuse and Alcoholism; Obesity; Overweight; Pharmaceutical Preparations; Pharmacology and Toxicology; Pharmacotherapy; Phase; Physicians; Pilot Projects; Population; Primary carcinoma of the liver cells; Process; Public Health; Research; Research Infrastructure; Research Personnel; Rural; Scientist; Services; Structure; Superfund; Teacher Professional Development; Text; Toxicology; United States National Institutes of Health; Universities; Viral hepatitis; career development; faculty mentor; faculty research; formative assessment; improved; liver injury; liver metabolism; liver transplantation; microbiome; microbiome research; multidisciplinary; non-alcoholic; non-alcoholic fatty liver disease; nonalcoholic steatohepatitis; novel therapeutics; opioid abuse; personalized medicine; problem drinker; programs; ranpirnase; recruit; research and development; senior faculty; success; toxicant; tumor immunology; viral liver disease

The University of Louisville Hepatobiology and Toxicology COBRE is a multidisciplinary group of investigators focusing on the liver and liver injury, gut:liver interactions, and liver:environment/toxicant/drug interactions, alcoholic and non-alcoholic liver injury, infectious liver diseases, liver cancer, and new liver therapies. The purpose of the administrative core is to provide administrative, fiscal and scientific oversight for this Phase II COBRE. This includes the overall career development and research goals of the Phase II COBRE (including formative and summative evaluation and specific milestones); the career development plans for junior faculty (including plans for transitioning to independence); plans for replacing key personnel (e.g., Project PIs, Core leaders, overall PI, pilot project PIs); oversight of the pilot projects; oversight of the biostatistical support services; and disseminating information to the lay and scientific communities. Liver diseases are some of the most common, rapidly increasing and poorly recognized health problems afflicting Americans. For example, Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis is the most common cause of abnormal liver enzymes in the US, affecting about 25% of adults and about 10% of children. Alcoholic Liver Disease is an increasing problem among those who drink. Importantly, there is no FDA-approved therapy for either NASH or ALD. Toxicant-Induced Liver Injury is an increasingly recognized industrial/environmental problem. Viral Liver Diseases (Hepatitis A, B, and C) remain major health problems related to drug abuse and homelessness. Hepatocellular carcinoma and Hepatitis C are major causes for liver related morbidity and liver transplantation in the US. Drug-Induced Liver Injury is the major reason new drugs do not come to market and the major cause of fulminant liver failure in the US. Personalized Medicine is increasingly recognized as an important aspect of drug therapy; and most drugs are metabolized in the liver. Building on the success of the Phase I COBRE Administrative Core, the specific aims of this Phase II COBRE Administrative Core are: 1. continue to provide overall administrative, fiscal and scientific oversight 2. enhance and grow the career development enterprise for project PIs 3. enhance and grow the career development/mentor development enterprise for the mentors 4. enhance and grow the research goals of the COBRE 5. continue to provide a process for replacing key personnel 6. continue to provide and enhance a summative and formative evaluation process for the COBRE, including specific milestones 7. continue to provide a robust pilot project program to grow the overall research goals of the COBRE 8. disseminate pertinent information to the scientific and lay community

路易斯维尔大学肝病学和毒理学cobre是一个多学科的小组 专注于肝脏和肝损伤的研究人员，肠道：肝脏相互作用和肝脏：环境/有毒物质/药物 相互作用，酒精和非酒精性肝损伤，感染性肝病，肝癌和新肝脏 疗法。行政核心的目的是为行政，财政和科学监督提供 该阶段II毛线。这包括第二阶段的整体职业发展和研究目标 毛病（包括形成性和总结性评估以及特定里程碑）；职业发展计划 对于初级教师（包括过渡到独立的计划）；更换关键人员的计划（例如 PIS项目，核心领导者，整体PI，PILOT PROVECT PIS）；监督飞行员项目；监督 生物统计支持服务；并将信息传播给外行和科学社区。 肝病是一些最常见的，迅速增长且认可的健康状况不佳 困扰美国人的问题。例如，非酒精性脂肪肝病/非酒精性脂肪性肝炎 是美国肝酶异常的最常见原因，影响约25％的成年人，约10％ 儿童。酒精性肝病是饮酒者的越来越多的问题。重要的是，没有 FDA批准的NASH或ALD疗法。毒物引起的肝损伤是越来越公认的 工业/环境问题。病毒肝病（乙型肝炎A，B和C）仍然是主要健康问题 与吸毒和无家可归有关。肝细胞癌和丙型肝炎是肝脏的主要原因 美国相关的发病率和肝移植。药物引起的肝损伤是新药的主要原因 不要上市，也不是在美国出现暴发肝衰竭的主要原因。个性化药物是 越来越被认为是药物治疗的重要方面；大多数药物都在肝脏中代谢。 基于I阶段Cobre行政核心的成功，该阶段II的具体目标 毛线行政核心是： 1。继续提供总体行政，财政和科学监督 2。增强和发展PIS项目的职业发展企业 3。为导师增强和发展职业发展/导师发展企业 4。增强和增强鞋底的研究目标 5。继续提供更换关键人员的过程 6。继续为毛豆提供并增强一个总结性和形成性评估过程， 包括特定的里程碑 7。继续提供强大的飞行员项目计划，以提高鞋底的整体研究目标 8。向科学和外行社区传播相关信息